Opportunist and serious infections in patients with neuroendocrine tumours treated with everolimus: A multicenter study of real world patients

Mauro, C.; Jesus, Victor Hugo Fonseca de; Barros, Milton; Costa, Frederico; Weschenfelder, Rui; D'Agustini, Nathalia; Ángel, Martín; Luca, Romina; Nuñez, Jose Eduardo; O’Connor, Juan Manuel; Riechelmann, Rachel P.

doi:10.1093/annonc/mdz256.015

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• For liver-predominant disease, hepatic embolisation can be used and repeated to treat progressive disease and/or refractory carcinoid syndrome, if adequate liver function is preserved [50]. • We suggest avoiding the use of everolimus during the pandemic because of the risk of severe and opportunistic infections [53].…”

Section: Neuroendocrine Tumoursmentioning

confidence: 99%

Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group

Riechelmann¹,

Peixoto²,

Fernandes³

et al. 2020

ecancer

View full text Add to dashboard Cite

As of 2020, the world is facing the great challenge of the COVID-19 (Coronavirus disease 2019) pandemic, caused by the SARS-CoV-2 virus. While the overall mortality is low, the virus is highly virulent and may infect millions of people worldwide. This will consequently burden health systems, particularly by those individuals considered to be at high risk of severe complications from COVID-19. Such risk factors include advanced age, cardiovascular and pulmonary diseases, diabetes and cancer. However, few data on the outcomes of cancer patients infected by SARS CoV-2 exist. Therefore, there is a lack of guidance on how to manage cancer patients during the pandemic. We sought to propose specific recommendations about the management of patients with gastrointestinal malignancies. Methods: The Brazilian Gastrointestinal Tumours Group board of directors and members sought up-to-date scientific literature on each tumour type and discussed all recommendations by virtual meetings to provide evidence-based-and sometimes, expert opinion-recommendation statements. Our objectives were to recommend evidence-based approaches to both treat and minimise the risk of COVID-19 for cancer patients, and simultaneously propose how to decrease the use of hospital resources at a time these resources need to be available to treat COVID-19 patients.

show abstract

Section: Neuroendocrine Tumoursmentioning

confidence: 99%